Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Does Glucagon-like Peptide 1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence?

Projekt: Typer af projekterProjekt

  • Fink-Jensen, Anders (Projektleder, faglig)
  • Klausen, Mette Kruse (Projektdeltager)
  • Jensen, Mathias Ebbesen (Projektdeltager)
  • Fisher, Patrick M. (Projektdeltager)
  • Macoveanu, Julian (Projektdeltager)
  • Thomsen, Gerda Krogh (Projektdeltager)
  • Benveniste, Helene (Projektdeltager)
  • Vilsbøll, Tina (Projektdeltager)
  • Knudsen, Gitte Moos (Projektdeltager)
  • Ekstrøm, Claus (Projektdeltager)
  • Miskowiak, Kamilla Woznica (Projektdeltager)
  • Becker, Ulrik (Projektdeltager)
  • Vollstaedt-Klein, Sabine (Projektdeltager)
  • Enghusen-Poulsen, Henrik (Projektdeltager)
  • Jørgensen, Niklas Rye (Projektdeltager)
  • Gillum, Matthew Paul (Projektdeltager)
  • Holst, Jens Juul (Projektdeltager)
  • Volkow, Nora D. (Projektdeltager)
Vis graf over relationer
Alcohol Use Disorder (AUD) is a global burden. The Glucagon-like peptide-1 (GLP-1) agonist exanetide, has proven to reduce alcohol consumption in preclinical experiments and may improve clinical care for patients with AUD.
Randomized, double-blinded, placebo-controlled, 26 week-long clinical trial, including 127 participants with AUD receiving exanetide or placebo once weekly. A subgroup of the participants had a Single-photon Emission Computed Tomography Scan (SPECT) and a Functional Resonance Imaging (fMRI) scan performed at baseline and follow-up.
Resultater (forventede):
Results will be published in 2021.
Diskussion/Impact (forventet):
We are the first internationally to investigate this potential new treatment in an RCT, so the trial will bring new and important knowledge to this field, no matter the outcome.


  • Sundhedsvidenskab - Substance-Related Disorders, Randomized Controlled Clinical Trial, Neuroimaging, Pharmacology

ID: 61947459